Northstrive Biosciences announced the initiation of Phase II of the AI Development Program with strategic partner Yuva Biosciences. As part of the Phase II objective, both companies will collaborate to leverage MitoNova, YuvaBio’s AI mitochondrial science-focused artificial intelligence platform, to compile a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases. YuvaBio will use MitoNova to virtually screen a large-scale library of diverse, drug-like small molecules and predict which candidates are most likely to promote mitochondrial health. YuvaBio will then analyze results of this screen, including chemical and bioactivity properties, to highlight opportunities for biological validation. Then, YuvaBio will compile an initial list of synthetic compounds for muscle preservation and metabolic health. Northstrive Biosciences, a PMGC (ELAB) Holdings, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- PMGC signs LOI to acquire California-based CNC machining company
- PMGC Holdings Signs LOI for U.S. Electronics Acquisition
- PMGC signs LOI to acquire electronics contract manufacturing company
- Northstrive announces completion of Phase 1 research, synthesis for EL-22
- Northstrive Biosciences Amends License Agreement with MOA Life